Shaff, who is currently chief operating and Financial officer, succeeds Roger J. Pomerantz, M.D. Shaff has also joined Seres' board of directors and will continue to serve as Seres' principal financial officer on an interim basis.
Pomerantz will continue as chairman of Seres' board of directors.
Shaff has served as Seres' chief financial officer, executive vice president and treasurer since November 2014, and in January 2018, he was appointed to the additional role of chief operating officer.
He also serves on the board of directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corp., where he was vice president of Finance for the Personalized Genetic Health division.
Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.
The company's lead programme, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection.
SER-287 is currently being evaluated in a Phase 2B study in patients with active mild-to-moderate ulcerative colitis.
Seres is advancing SER-401 to augment the efficacy of immuno-oncology treatment.
In addition, the company has several other microbiome therapeutic candidates in preclinical development for various serious diseases.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT